Suzhou Abogen Biosciences Co., Ltd.

This early-stage trial is testing a new mRNA vaccine called ABO1108 to prevent shingles in adults aged 40 and above. Around 180 healthy volunteers will receive two shots of either the new vaccine at different doses, a placebo, or the existing Shingrix vaccine. The main goal is to…

This study tests a new mRNA vaccine called ABO1108 to see if it can prevent shingles in adults aged 40 and above. About 300 healthy volunteers will receive two shots, two months apart, and be compared to a placebo group. The goal is to measure the immune response and check for sa…

This phase 2 trial is testing a new mRNA vaccine called ABO1105 against respiratory syncytial virus (RSV) in 420 healthy adults aged 50 and older. Participants receive either a low or high dose of the vaccine or a placebo. The study measures how well the vaccine boosts antibodies…

This early-stage trial tests a new mRNA vaccine called ABO1105 against respiratory syncytial virus (RSV). Around 96 healthy adults aged 18 and older will receive either the vaccine or a placebo. The main goal is to check if the vaccine is safe and triggers an immune response.